Abstract 1985P
Background
Sarcomas are rare mesenchymal tumors that require multidisciplinary care. Referral centres receiving patients (pts) from peripheral set-ups face challenges which highlight the need for expert sarcoma pathology and specialised treatment.
Methods
This is a retrospective study in pts referred with pathological and/or clinico-radiological diagnosis of sarcoma (January 2021 to December 2022). Clinical, diagnostic, prior treatment details were reviewed from records. Pathologic discordances (PD) were classified as major (sarcoma to carcinoma or benign, soft tissue sarcoma to bone sarcoma or vice versa, any change influencing treatment) or minor.
Results
539 pts included (incl) 58% males (n=312) with median age of 35 (1-89 years), residing at median distance of 160 kilometres (km) (3-2600) from our centre. Median presenting time was 11 months (15 days-20 years) from symptom onset; recurrent/metastatic (n=255, 47%) and locally advanced (n=134, 25%) stages predominated. Common primary sites were extremity (45.5%), abdomen (27%) with symptoms of pain (67%) and swelling (64%). 499 (92.5%) pts had pathology reports from outside and available comparison (n=372) showed 42.9% discordance (16.3% major, 26.6% minor) (Table). Sarcoma diagnosis changed to benign (1.3%), carcinoma (1.3%), fibromatosis (0.2%), germ cell tumor (0.2%) after review. Ultra-rare sarcomas (URS) (n=33, 6%) showed higher PD (73%). Molecular testing was done in 4.6% (n=11) of pts with testing indications. Most had received treatment outside (surgery in 50.6%, chemotherapy in 32.6%); deviation from standard guidelines was noted in 39.7% chemotherapy and 8.7% surgeries (Table). Univariate analysis did not yield significant factors associated with diagnostic or treatment discordance. Table: 1985P
Details of subjects and discordances in diagnosis and treatment
Diagnosis | Treatment |
Subtypes Soft tissue sarcoma (STS) = 295 (54.7%) Bone sarcoma (BS) = 100 (18.5%) Carcinoma = 7 (1.2%) Benign = 7 (1.2%) Others = 10 (2%) Undifferentiated = 1 (0.2%) Discordances a) Major = 61 (16.3%) b) Minor = 99 (26.6%) Major discordance: a) Change of sarcoma subtype = 39 (64%) b) Benign to malignant = 14 (11.7%) c) Carcinoma to sarcoma = 4 (6.5%) d) Low to high grade = 4 (6.5%) e) BS to STS = 3 (5%) | Chemotherapy a) Incorrect regimen (n=28, 16%) b) Inadequate dose/cycles (n=20, 11.3%) c) Not given despite indication (n=17, 9.6%) d) Others (n=4, 2.2%) Surgery a) Inadequate surgery (n=19, 7%) b) Surgery without staging (n=5, 2%) |
Conclusions
The significant discrepancies noted in diagnosis and management of pts in this study highlight the importance of expert pathologists and early referral for better treatment outcomes in sarcomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15
1930P - phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Presenter: Young Saing Kim
Session: Poster session 15
1931P - Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study
Presenter: MIng-Jing Lee
Session: Poster session 15
1932P - First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Presenter: Jose Antonio González
Session: Poster session 15
1933P - Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Presenter: Thibaud Bertrand
Session: Poster session 15
1934P - Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
Presenter: Brian Van Tine
Session: Poster session 15
1935P - Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response
Presenter: Wang Xiang-Xu
Session: Poster session 15
1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Presenter: Marcus Renner
Session: Poster session 15
1937P - KM-subtraction meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
Presenter: Qin Jian Low
Session: Poster session 15
1938P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Presenter: Maria Aguado Sorolla
Session: Poster session 15